Nobuaki Toyoda
University of Tokyo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nobuaki Toyoda.
Biochemical and Biophysical Research Communications | 2002
Hong-Yan Dong; Nobuaki Toyoda; Hiroyuki Yoneyama; Makoto Kurachi; Tadashi Kasahara; Yoshiro Kobayashi; Hidekuni Inadera; Shin-ichi Hashimoto; Kouji Matsushima
Fulminant hepatic failure (FHF) is a disease characterized by sudden and severe impairment of liver function. To elucidate the mechanism involved in FHF, we adopted a murine model of FHF by administrating mice with heat-killed Propionibacterium acnes (P. acnes), followed by a low dose of lipopolysaccharide (LPS), and analyzed the dynamic change of gene expression profile of the murine liver using an in-house cDNA microarray system which contained most of the cDNAs encoding chemokines/cytokines and their receptors (33 chemokines/21 chemokine receptors, 28 cytokines/35 cytokine receptors) as well as 230 liver related proteins mostly selected by serial analysis of gene expression (SAGE). Among them, 335 genes were found to differ by more than 2-fold in at least one time point comparing with normal liver. Hierarchical cluster analysis revealed that except for a few genes, such as heme oxygenase (HO)-1 and nicotinamide N-methyltransferase (NNMT) of which expression increased, the expression of most of the genes encoding drug metabolizing enzymes decreased with the progress of the disease. The expression of the genes encoding chemokines/cytokines was dramatically changed, such as Mig, IP-10, RANTES, TNF-alpha, and IFN-gamma. In addition, the expression of those that were not previously linked to this murine model was also identified to be changed. These include endogenous IL-18 binding protein (IL-18BP), CXCL16 (the ligand of Bonzo, CXCR6) as well as ESTs. Taken together this study has shown the systemic and comprehensive gene expression profile during FHF and may contribute to better understanding of the mechanism of FHF.
Blood | 2000
Takuji Suzuki; Shinichi Hashimoto; Nobuaki Toyoda; Shigenori Nagai; Nobuyuki Yamazaki; Hong-Yan Dong; Jun Sakai; Taro Yamashita; Toshihiro Nukiwa; Kouji Matsushima
Blood | 2000
Shinichi Hashimoto; Takuji Suzuki; Shigenori Nagai; Taro Yamashita; Nobuaki Toyoda; Kouji Matsushima
International Immunology | 2001
Shigenori Nagai; Shinichi Hashimoto; Taro Yamashita; Nobuaki Toyoda; Taku Satoh; Takuji Suzuki; Kouji Matsushima
Biochemical and Biophysical Research Communications | 2000
Taro Yamashita; Shinichi Hashimoto; Shuichi Kaneko; Shigenori Nagai; Nobuaki Toyoda; Takuji Suzuki; Kenichi Kobayashi; Kouji Matsushima
Biochemical and Biophysical Research Communications | 2000
Hidekuni Inadera; Shin-ichi Hashimoto; Hong-Yan Dong; Takuji Suzuki; Shigenori Nagai; Taro Yamashita; Nobuaki Toyoda; Kouji Matsushima
Biochemical and Biophysical Research Communications | 2001
Taro Yamashita; Shuichi Kaneko; Shin-ichi Hashimoto; Taku Sato; Shigenori Nagai; Nobuaki Toyoda; Takuji Suzuki; Kenichi Kobayashi; Kouji Matsushima
Blood | 2003
Shinichi Hashimoto; Shigenori Nagai; Jun Sese; Takuji Suzuki; Aya Obata; Taku Sato; Nobuaki Toyoda; Hong-Yan Dong; Makoto Kurachi; Tomoyuki Nagahata; Ken‐ichi Shizuno; Shinichi Morishita; Kouji Matsushima
International Immunopharmacology | 2004
Kazushi Motomura; Nobuaki Toyoda; Kazunori Oishi; Hironori Sato; Shigenori Nagai; Shin-ichi Hashimoto; Sitefano Buguruka Tugume; Richard Enzama; Roy Mugewa; Cissy Kityo Mutuluuza; Peter Mugyeyi; Tsuyoshi Nagatake; Kouji Matsushima
Genome Research | 2003
Nobuaki Toyoda; Shigenori Nagai; Yuya Terashima; Kazushi Motomura; Makoto Haino; Shinichi Hashimoto; Hajime Takizawa; Kouji Matsushima